Sigma receptor modulators: A patent review

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 5, 2013, Pages 597-613

  Collina, Simona ^a   Gaggeri, Raffaella ^a   Marra, Annamaria ^a   Bassi, Andrea ^a   Negrinotti, Sara ^a   Negri, Francesca ^a   Rossi, Daniela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Acute and chronic neurodegenerative pathologies; Agonist; Alzheimer's disease; ANAVEX 2 73; Antagonist; Central nervous system diseases; E 52862; Neuropathic pain; SA4503; Sigma receptor

Indexed keywords

1 PHENYLCYCLOHEXANECARBOXYLIC ACID 2 MORPHOLINOETHYL ESTER; 2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; 4 IBP; ALPHA (4 FLUOROPHENYL) 4 (5 FLUORO 2 PYRIMIDINYL) 1 PIPERAZINEBUTANOL; AMINO ACID RECEPTOR AFFECTING AGENT; ANAVEX 2 73; BD 1018; BD 1063; CAPTODIAMINE; CUTAMESINE; E 52862; EP 0512525; EP 0711763; EP 0839805; EP 0870758; EP 572952; IGMESINE; N ALLYLNORMETAZOCINE; RC 33; RIMCAZOLE; SIGMA OPIATE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; US 4709094; US 5116846; US 5180729A; US 5731331; WO 9112797; WO 9118868; WO 9204054; WO 9218127; WO 9325527; WO 9959409;

ADDICTION; BINDING AFFINITY; DRUG STRUCTURE; HUMAN; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NONHUMAN; PATENT; REVIEW;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; NEOPLASMS; NEURALGIA; NEURODEGENERATIVE DISEASES; PATENTS AS TOPIC; RECEPTORS, SIGMA;

EID: 84876567515     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.769522     Document Type: Review

References (80)

1. Walker JM, Bowen WD, Walker FO, et al. Sigma receptors: biology and function. Pharmacol Rev 1990;42:355-402
2. Mavlyutov TA, Epstein ML, Andersen KA, et al. The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study. Neuroscience 2010;167(2):247-55
3. Hanner M, Moebius FF, Flandorfer A, et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci USA 1996;93(15):8072-7 (Pubitemid 26277167)
4. Seth P, Fei YJ, Li HW, et al. Cloning and functional characterization of a sigma receptor from rat brain. J Neurochem 1998;70(3):922-31 (Pubitemid 28113624)
5. Toussaint M, Debreu-Fontaine MA, Maurice T, Melnyk P. New synthesis of tic-hydantoins sigma-1 ligands and pharmacological evaluation on cocaine-induced stimulant effects. Med Chem 2010;6(6):355-73
6. Hayashi T, Rizzuto R, Hajnoczky G, Su TP. MAM: more than just a housekeeper. Trends Cell Biol 2009;19(2):81-8
7. Su TP, Hayashi T, Maurice T, et al. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol Sci 2010;31(12):557-66
8. Morin-Surun MP, Collin T, Denavit-Saubie M, et al. Intracellular sigma1 receptor modulates phospholipase C and protein kinase C activities in the brainstem. Proc Natl Acad Sci USA 1999;96(14):8196-9 (Pubitemid 29328431)
9. Zeng C, Vangveravong S, Xu J, et al. Subcellular localization of sigma-2 receptors in breast cancer cells using two-photon and confocal microscopy. Cancer Res 2007;67:6708-16 (Pubitemid 47105517)
10. McLean S, Weber E. Autoradiographic visualization of haloperidol- sensitive sigma receptors in guinea-pig brain. Neuroscience 1988;25:259-69
11. Dumont M, Lemaire S. Interaction of 1,3-di(2-[5-3H]tolyl) guanidine with sigma 2 binding sites in rat heart membrane preparations. Eur J Pharmacol 1991;209:245-8
12. Ela C, Barg J, Vogel Z, et al. Sigma receptor ligands modulate contractility, Ca* influx and beating rate in cultured cardiac myocytes. J Pharmacol Exp Ther 1994;269:1300-9 (Pubitemid 24204218)
13. Jansen KL, Elliot M, Leslie RA. Sigma receptors in rat brain and testes show similar reductions in response to chronic haloperidol. Eur J Pharmacol 1992;214:281-3
14. Roman F, Pascaud X, Chomette G, et al. Autoradiographic localization of sigma opioid receptors in the gastrointestinal tract of the guinea pig. Gastroenterology 1989;97(1):76-82 (Pubitemid 19190999)
15. Maurice T, Su T-P. The pharmacology of sigma-1 receptors. Pharmacol Ther 2009;124:195-206
16. Kulkarni SK, Dhir A. tau-1 receptors in major depression and anxiety. Expert Rev Neurother 2009;9:1021-34
17. Bermack JE, Debonnel G. The role of sigma receptors in depression. J Pharmacol Sci 2005;97:317-36 (Pubitemid 40515745)
18. Snyder SH, Largent BL. Receptor mechanisms in antipsychotic drug action: focus on sigma receptors. J Neuropsychiatry Clin Neurosci 1989;1:7-15 (Pubitemid 19247047)
19. Luty AA, Kwok JB, Dobson-Stone C, et al. Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. Ann Neurol 2010;68(5):639-49
20. Guzman-Lenis MS, Navarro X, Casas C. Selective sigma receptor agonist 2-(4-morpholinethyl)1-phenylcyclohexanecarboxylate (PRE084) promotes neuroprotection and neurite elongation through protein kinase C (PKC) signaling on motoneurons. Neuroscience 2009;162:31-8 promote neuroprotection.
21. Rossi D, Pedrali A, Urbano M, et al. Identification of a potent and selective receptor agonist potentiating NGF-induced neurite outgrowth in PC12 cells. Bioorg Med Chem 2011;19:6210-24
22. Ostenfeld MS, Fehrenbacher N, Høyer-Hansen M, et al. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res 2005;65:8975-83 (Pubitemid 41377389)
23. Megalizzi V, Mathieu V, Mijatovic T, et al. 4-IBP, a sigma1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs. Neoplasia 2007;9:358-69 (Pubitemid 46799979)
24. University of Oregon. Sigma Brain Receptor Ligands and Their Use. US4709094; 1986
25. University of Oregon. Substituted guanidines having high binding to the sigma receptor and the use thereof. WO9118868; 1991
26. University of Oregon. Tri-and tetra-substituted guanidines and their use as excitatory amino acid antagonists. WO9112797; 1991
27. State of Oregon, Oregon State Board of Higher Education, Oregon Health Sciences University, The University of Oregon. Substituted amidines having high binding to the sigma receptor and the use thereof. WO9204054; 1992
28. E.I. Du Pont De Nemours and Co. Antipsychotic 1-cycloalkylpiperidines. WO9103243; 1990
29. Du Pont Merck Pharmaceutical Co. Use of sigma receptor antagonists to enhance the effects of antipsychotic drugs. WO9218127; 1991
30. Du Pont Merck Pharmaceutical Co. Use of sigma receptor antagonists for treatment of cocaine abuse. US5180729; 1993
31. Du Pont Merck Pharmaceutical Co. Use of sigma receptor antagonists for treatment of amphetamine abuse. WO9214463; 1992
32. Du Pont Merck Pharmaceutical Co. N-Aralkyl piperidine derivatives as psychotropic drugs. US5116846; 1990
33. Du Pont Merck Pharmaceutical Co. (NPhthalimidoalkyl) piperidines for the treatment of psychoses. WO9322310; 1993
34. Du Pont Merck Pharmaceutical Co. Hydroisoindolines and hydroisoquinolines as psychotropic. US5216018; 1992
35. Hellewell SB, Bowen WD. A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain Res 1990;527:244-53 (Pubitemid 20289511)
36. Iyengar S, Wood PL, Mick SJ. (+) 3-[3-hydroxyphenyl-N-(1-propyl) piperidine] selectively differentiates effects of sigma ligands on neurochemical pathways modulated by sigma receptors: evidence for subtypes, in vivo. Eur J Pharmacol 1991;183(6):2336-7
37. Otsuka Pharmaceutical Co. Ltd. Carbostyril derivatives and pharmaceutical compositions. EP0512525; 1992
38. H. Lundbeck A/S. Dimeric piperidine, tetrahydropyridine and piperazine derivatives. WO9325527; 1993
39. Ferrer Internacional S.A. 4-Benzylpiperidine derivatives, a process for preparing them and pharmaceutical compositions containing them. EP0572952; 1993
40. Santen Pharmaceutical Co. Ltd. Novel 1,4-Di(Phenylalkyl) piperazine derivative. EP0711763; 1994
41. Taisho Pharmaceutical Co. Ltd. Optically active substituted phenylalkylamine derivatives. EP0870758; 1996
42. Schering Aktiengesellschaft. Pyrrolidinone derivatives and their use as antipsychotic medicaments. EP0839805; 1997
43. Laboratorios del Dr. Esteve S.A. Tetrahydropyridine-(or 4 hydroxypiperidine) alkylazoles having an affinity for sigma and-or 5HT1a receptors. US5731331; 1998
44. Matsumoto. Sigma receptor antagonists having anti-cocaine properties and uses thereof. WO9959409; 1999
45. Cambridge Neuroscience, Inc., Virginia Commonwealth University. Sigma receptor ligands and the use thereof. US6087346; 2000
46. Glennon RA, Ablordeppey SY, Ismaiel AM, et al. Structural features important for sigma(1) receptor-binding. J Med Chem 1994;37(8):1214-19 (Pubitemid 24145383)
47. Glennon RA, Yousif MY, Ismaiel AM, et al. Novel 1-phenylpiperazine and 4-phenylpiperidine derivatives as high-affinity sigma ligands. J Med Chem 1991;34(12):3360-5
48. Glennon RA, Ismaiel AM, Smith JD, et al. Binding of substituted and conformationally restricted derivatives of n-(3-phenyl-n-propyl)-1-phenyl-2- aminopropane at sigma-receptors. J Med Chem 1991;34(6):1855-9
49. Glennon RA, Battaglia G, Smith JD. (-) PPAP: a new and selective ligand for sigma-binding sites. Pharmacol Biochem Behav 1990;37(3):557-9
50. H. Lundbeck A/S. Piperidine derivates having anxiolytic effect. US6031099; 2000
51. Warner-Lambert Co, Ely Lilly and Co. A pharmaceutical combination for the treatment Of depression. WO0041684; 1999
52. Warner-Lambert Co. Novel uses of sigma receptor agonists. WO0115685; 2000
53. Matsuno K, Kobayashi T, Tanaka MK, et al. Sigma 1 receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test. Eur J Pharmacol 1996;312(3):267-71 (Pubitemid 26323508)
54. Merck Patent GMBH. Use of defined substances that bind to the sigma receptor for combating sarcoma and carcinoma. WO0230422; 2001
55. M's Science Corp. Sigma ligands for neuronal regeneration and functional recovery. WO07053580; 2006
56. Lobner D, Lipton P. Sigma-ligands and non-competitive NMDA antagonists inhibit glutamate release during cerebral ischemia. Neurosci Lett 1990;117:169-74 (Pubitemid 20284094)
57. Nakazawa M, Matsuno K, Mita S, et al. Activation of sigma1 receptor subtype leads to neuroprotection in the rat primary neuronal cultures. Neurochem Int 1998;32:337-43 (Pubitemid 28174985)
58. Vamvakides Alexandre. New sigma(s) receptor ligands with anti-apoptotic and/or pro-apoptotic properties over cellular biochemical mechanism, with neuroprotective, anti-cancer, anti-metastatic and anti-(chronic) inflammatory action. WO08087458; 2008
59. Vamvakides Alexandre. Sigma(s) receptor ligands with anti-apoptotic and/or pro-apoptotic properties over cellular mechanism, exhibiting prototypical cytoprotective and also anticancer activity. WO10097641; 2010
60. Wisconsin Alumni Research Foundation. Sigma-1 receptor ligands and methods of use. US100179111; 2009
61. Laboratorios del Dr. Esteve, S.A. Sigma receptor inhibitors. WO06021462; 2006
62. Laboratorios del Dr. Esteve, S.A. 1,2,4-Triazole derivatives as sigma receptor inhibitors. EP1921073A1; 2006
63. Laboratorios del Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof. EP2353591; 2010
64. Laboratorios del Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia. EP2415471; 2010
65. Laboratorios del Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof. US110112095; 2009
66. Laboratorios del Dr. Esteve, S.A. 4,5,6,7-tetrahydrobenzo[B]thiophene derivatives and their use as sigma receptor ligands. US8227625; 2012
67. Laboratorios del Dr. Esteve, S.A. Substituted pyrazole sigma receptor antagonists. US110015183; 2011
68. Laboratorios del Dr. Esteve, S.A. 2-(1-phenyl-4,5,6,7-tetrahydro-1h- indazol-4-Yl)ethylamine derivatives useful as sigma receptor inhibitors. WO12072791; 2011
69. Laboratorios del Dr. Esteve, S.A. Spiro [piperidine-4-4'-thieno [3,2-c]pyran] derivatives and related compounds as inhibitors on the sigma receptor for the treatment of psychosis. WO08155132; 2008
70. Laboratorios del Dr. Esteve, S.A. Spiro [Benzopyran] Or Spiro[Benzofuran] Derivatives Which Inhibit The Sigma Receptor. WO07121976; 2007
71. Laboratorios del Dr. Esteve, S.A. Spiro-Pyrano-Pyrazole Derivatives. WO08125349; 2008
72. Laboratorios del Dr. Esteve, S.A. Pyrano-Pyrazole-Amines. WO08125348; 2008
73. The University of Mississippi. Highly selective sigma receptor ligands. WO09026227; 2008
74. University College Dublin, National University of Ireland. Psycho-pharmaceuticals. WO09128057; 2009
75. Martin WR, Eades CG, Thompson JA, et al. The effects of morphine-and nalmorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976;197(3):517-32
76. Gundlach AL, Largent BL, Snyder SH. Phencyclidine and sigma opiate receptors in brain: biochemical and autoradiographical differentiation. Eur J Pharmacol 1985;113(3):465-6 (Pubitemid 16249856)
77. Quirion R, Bowen WD, Itzhak Y, et al. A proposal for the classification of the sigma binding sites. Trends Pharmacol Sci 1992;13(3):85-6
78. Wilke RA, Mehta RP, Lupardus PJ, et al. Sigma receptor photolabeling and sigma receptor-mediated modulation of potassium channel in tumor cells. J Biol Chem 1999;274:18387-92
79. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell 2007;131(3):596-610 (Pubitemid 350017760)
80. Hayshi T, Su TP. Sigma-1 receptor ligands: potential in treatment of neuropsychiatric disorders. CNS Drug 2004;18(5):269-84